This is a routine shelf registration with no immediate capital raise. Monitor for future prospectus supplements that would disclose actual offering terms, size, and use of proceeds. The company's clinical-stage biotech profile and existing short interest (~15.8%) suggest any future equity offering could face above-average dilution sensitivity.
Drug in focus
TYRA drug pipeline →dabogratinib
◆ Mixed Named in this S-3ASR- Impact
- Phase
- Phase 2
- Time to market
- Dabogratinib is in Phase 2 development across all three indications. A pivotal Phase 3 study in NMIBC is being planned following the SURF302 data, but no specific start date has been given. The earliest potential approval would likely be several years away, contingent on successful Phase 3 data and FDA review.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the BEACH301 Phase 2 safety sentinel cohort data in pediatric achondroplasia, expected by end of Q1 2027. Positive safety and growth data could re-rate the stock after the September 2026 SURF302 selloff; negative safety signals would damage the achondroplasia thesis. Separately, watch for details on a planned pivotal Phase 3 study in NMIBC, which would be the next major binary event for the bladder cancer program.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $25.07entry
- T+1 · 2mo ago +1.44%α +1.89% · $25.43
- T+5 · 8w ago +2.31%α +2.21% · $25.65
- T+20 · 5w ago −21.82%α −24.08% · $19.60
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tyra Biosciences filed an automatic shelf registration statement (S-3ASR) on September 14, 2026, registering an unspecified amount of common stock, preferred stock, debt securities, warrants, and units for potential future sale. The filing is a standard shelf registration by a well-known seasoned issuer (WKSI), allowing the company to access capital markets opportunistically. No specific offering size, pricing, or immediate dilution is disclosed, making this a routine capital-markets housekeeping filing with no immediate trading impact.
Key Facts
- Tyra Biosciences filed an automatic shelf registration statement (S-3ASR) on September 14, 2026.
- The registration covers an unspecified amount of common stock, preferred stock, debt securities, warrants, and units.
- The filing fee is deferred under Rules 456(b) and 457(r), with no registration fee paid at this time.
- The company is a well-known seasoned issuer (WKSI) as defined in Rule 405 under the Securities Act.
- No specific offering size, price, or terms are disclosed in the filing.
- The company's common stock closed at $22.03 per share on September 11, 2026, with a market cap of $1.3B.
- The company has a history of 3 offering/registration filings in the last 24 months, including this one.
- Short interest is 9.4M shares (~15.8% of estimated shares outstanding) as of August 31, 2026.
Financial Impact
No specific offering size or dollar amount disclosed; registration fee deferred. Potential future dilution is unspecified.
Risk Factors
- Potential future equity dilution from unspecified shelf takedowns.
- Clinical-stage biotech with no approved products; capital needs may necessitate future offerings.
- Elevated short interest (~15.8%) could amplify price moves on any future offering announcement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3ASR Filing (Primary) | 0001193125-26-389752 |
| Document: d49930ds3asr.htm | 0001193125-26-389752 |
| Document: d49930dexfilingfees.htm | 0001193125-26-389752 |
| Document: d49930dex51.htm | 0001193125-26-389752 |
| Document: d49930dex231.htm | 0001193125-26-389752 |
| Document: 0001193125-26-389752-index-headers.html | 0001193125-26-389752 |
| Document: 0001193125-26-389752-index.html | 0001193125-26-389752 |
| Document: 0001193125-26-389752.txt | 0001193125-26-389752 |
Track record
13 reports on TYRA
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $21.00 Now $19.74 −6.00% settles Nov 17
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
- Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
- Sep 14, 20269w ago S-3ASR Neutral 3/10 Viewing Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
- Aug 4, 202614w ago 424B5 Bearish 6/10 Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
- May 13, 202626w ago 8-K Mixed 5/10 Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
- Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers